Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta‐analysis
Addiction2017Vol. 113(3), pp. 545–563
Citations Over TimeTop 1% of 2017 papers
Lucy Platt, Silvia Minozzi, Jennifer Reed, Peter Vickerman, Holly Hagan, Clare E. French, Ashly E. Jordan, Louisa Degenhardt, Vivian Hope, Sharon Hutchinson, Lisa Maher, Norah Palmateer, Avril Taylor, Julie Bruneau, Matthew Hickman
Abstract
Opioid substitution therapy reduces risk of hepatitis C acquisition and is strengthened in combination with needle and syringe programmes (NSP). There is weaker evidence for the impact of needle syringe programmes alone, although stronger evidence that high coverage is associated with reduced risk in Europe.
Related Papers
- → Management of women treated with buprenorphine during pregnancy(2011)31 cited
- → Pharmacological Management of Opioid Use Disorder in Pregnant Women(2015)30 cited
- → A Single Dose of 55 mg of Buprenorphine for the Treatment of Heroin Dependence: A New Result(2016)12 cited
- → When treating pregnant women with opioid use disorder, the benefits of using opioid maintenance treatment outweigh the risks(2016)1 cited
- → Buprenorphine Versus Methadone for Opioid Use Disorder in Pregnancy(2023)1 cited